Learning Objectives. Epidemiology of Acute Coronary Syndrome
|
|
- Bryan Singleton
- 5 years ago
- Views:
Transcription
1 Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet therapy plan for a patient who has suffered an acute coronary syndrome (ACS) Review recently published primary literature of antiplatelet therapy in ACS Discern patient-specific factors necessary to consider in the selection of antiplatelet therapies in ACS Epidemiology of Acute Coronary Syndrome Cardiovascular disease accounts for approximately 1 in 3 deaths in the United States Coronary heart disease is the leading cause of this (45.1%) Every 40 seconds an American will suffer a heart attack (ACS) From 2004 to 2014 annual deaths attributable to coronary disease has declined but remains very high ACS and coronary heart disease represent 2 of the 10 most expensive hospital discharge diagnoses Circulation. 2017; 135:e
2 J Am Coll Cardiol. 2014;64:e Patient Case JS is 74 YO M PMH HTN HLD TIA in 2014 PSH 40 pack-year history smoking Presents with significant chest pain, diaphoretic Receives aspirin 325mg chewable and nitroglycerin 0.4mg SL in ED, started on UFH infusion Chest pain is relieved TnI 4.1ng/mL; CK-MB 9.5ng/mL EKG ST depressions in V2-V4 with T-wave inversions; no ST elevations noted Patient Case What is the patient likely suffering from? A. Indigestion B. Unstable angina C. Non-STEMI ACS D. STEMI ACS 2
3 Pharmacotherapy in Acute Coronary Syndrome Aspirin Beta-blockers (non-shock) P2Y12 Receptor Antagonist ACS Nitroglycerin GP IIb/IIIa Inhibitors (select patients) Heparin or LMWH 3
4 Guidelines 2013 ACCF/AHA Guideline for the Management of STEMI Aspirin mg prior to primary PCI (Class I; LOE B) Should be continued indefinitely mg (Class I; LOE A) 81 mg preferred maintenance dose (Class IIa; LOE B) Loading dose of P2Y12 receptor inhibitor as early as possible or at time of primary PCI Clopidogrel 600mg (Class I; LOE B) Prasugrel 60mg (Class I; LOE B) Ticagrelor 180mg (Class I; LOE B) P2Y12 inhibitor continued for 1 year with DES or BMS (Class I; LOE B) Continue beyond 1 year if DES (Class IIb; LOE C) No prasugrel in patient with history of stroke/tia (Class III; LOE B) J Am Coll Cardiol. 2013;61:e ACCF/AHA Guideline for the Management of STEMI IV GP IIb/IIIa receptor antagonists in conjunction with UFH or bivalirudin Abciximab (Class IIa; LOE A) Tirofiban (Class IIa; LOE B) Eptifibatide (Class IIa; LOE B) Pre-catheterization laboratory administration (Class IIb; LOE B) Intracoronary abciximab (Class IIb; LOE B) J Am Coll Cardiol. 2013;61:e
5 2014 AHA/ACC Guideline for the Management of Patients with NSTEMI ACS Aspirin (non-enteric coated) mg as soon as possible and maintenance mg daily indefinitely (Class I; LOE A) P2Y12 inhibitor should be administered up to 12 months to all patients with NSTE-ACS treated with early invasive or ischemia-guided strategy Clopidogrel mg loading then 75mg daily (Class I; LOE B) Ticagrelor 180mg loading then 90mg twice daily (Class I; LOE B) Ticagrelor preferred over clopidogrel (Class IIa; LOE B) Prasugrel may be option to continue in post-pci patients treated with coronary stents (Class I; LOE B) GP IIb/IIIa inhibitor (eptifibatide and tirofiban) in patients treated with early invasive strategy with intermediate/high risk features (Class IIb; LOE B) Not recommended in all NSTEMI ACS At time of PCI in patient not pre-treated with P2Y12inhibitor (Class I; LOE A) J Am Coll Cardiol. 2014;64:e ACC/AHA Guideline Focused Update on Duration of DAPT in CAD In patients with any ACS treated with stent implantation or NSTE-ACS treated medically, it is reasonable to use ticagrelor over clopidogrel (Class IIa, LOE B) In patients with any ACS treated with stent implantation without high risk of bleeding and no history of stroke/tia, it is reasonable to use prasugrel over clopidogrel (Class IIa, LOE B) Prasugrel should not be administered to patients with prior history of stroke or TIA (Class III, LOE B) J Am Coll Cardiol. 2016;68: ACC/AHA Guideline Focused Update on Duration of DAPT in CAD In patients treated with DAPT, a daily dose of 81mg (75-100mg) daily is recommended (Class I, LOE B) In ACS patients treated with DAPT after stent implantation, a P2Y12 inhibitor should be given at least 12 months (Class I, LOE B) With high risk of bleeding (treatment with oral anticoagulant) or at high risk of severe bleeding 6mo may be reasonable (Class IIb, LOE C) In patients without high risk of bleeding or taking oral anticoagulants >12mo may be reasonable (Class IIb, LOE A) DAPT Score may help define who could benefit J Am Coll Cardiol. 2016;68:
6 J Am Coll Cardiol. 2016;68: What s changed? Maintenance aspirin dose always 81mg Ticagrelor or prasugrel may be recommended over clopidogrel following ACS GP IIb/IIIa lower recommendation Strongest indication remains NSTEMI patient undergoing PCI not pretreated with oral P2Y12 inhibitor Duration of DAPT may be variable based on multiple factors 12mo still seems optimal in ACS patients Oral P2Y12 inhibitor therapy 6
7 Selection of Oral P2Y12 inhibitor Clopidogrel Prasugrel Ticagrelor Cyclopentyltiazolopyrimidine Thienopyridine Thienopyridine Chemical class mg LD 60mg LD 180mg LD Dose 75mg daily 10mg daily 90mg twice daily On strong CYP 2C19 On strong CYP 3A4- Contraindications History of stroke/tia inhibiting drugs inducing drugs Binding Irreversible Irreversible Reversible Onset of activity 2-6hrs 30min 30min Duration of effect 3-10 days 7-10 days 3-5 days Recommended withdrawal 5 days 7 days 5 days before surgery Yes, with variable Yes; with predictable No; active drug with Pro-drug metabolism metabolism active metabolite Generic available Yes No No Patient on DAPT plus ACS patient with or Favored situation ACS patient with PCI anticoagulation without PCI Eur Heart J. 2016;37: Prasugrel in ACS patients receiving PCI TRITON-TIMI 38 trial Prasugrel vs clopidogrel in ACS patients undergoing PCI Loading dose of clopidogrel group 300mg GP IIb/IIIa inhibitor use ~54% Primary endpoint CV death, nonfatal MI, stroke Within 3 days of PCI vs 4.7% (p=0.01) 3 days and beyond 6.9 vs 5.6% (p=0.003) History of stroke or TIA no benefit and greater risk of safety events Composite death, nonfatal MI, stroke,timi major bleeding 16 vs 23% (p=0.04) N Engl J Med. 2007;357: Ticagrelor in ACS PLATO trial Ticagrelor vs clopidogrel in patients with ACS STEMI comprised 37.7% PCI during index hospitalization 61% GP IIb/IIIa inhibitor use 26.6% Primary outcome Death from vascular causes, MI, or stroke HR 0.84 ( ) Safety endpoints No difference in study-defined or TIMI major bleeding More fatal intracranial bleed N Engl J Med. 2009;361:
8 Ticagrelor >12mo PEGASUS-TIMI 54 Ticagrelor 90mg vs ticagrelor 60mg vs placebo Enrolled patients with MI 1-3 years prior continuing DAPT Primary efficacy Outcome Death, MI, Stroke Similar between ticagrelor groups Both better than placebo Safety All bleeding outcomes increased on both ticagrelor groups N Engl J Med. 2015;372: DAPT Score Evaluation in patients who receive stent implantation Randomized to receive placebo or thienopyridine at 12mo s/p PCI Clopidogrel or prasugrel Aimed to determine optimal duration of DAPT based on risk factors Predictors of bleeding and MI/Stent thrombosis JAMA. 2016;315: Score <2 Score 2 JAMA. 2016;315:
9 Patient Case JS undergoes successful PCI of left anterior descending coronary artery and circumflex coronary artery with placement of two everolimus-eluting stents. Patient has received aspirin 325mg orally x 1 dose Patient Case What would be the most appropriate plan for dual antiplatelet therapy for JS? A. Ticagrelor 180mg loading dose then 90mg BID plus aspirin 81mg daily for at least 12months. B. Prasugrel 60mg loading dose then 10mg daily plus aspirin 81mg daily for 1 month C. Clopidogrel 300mg loading dose then 75mg daily plus aspirin 81mg daily for 6 months. D. Ticagrelor 180mg loading dose then 90mg BID plus aspirin 325mg daily for 12 months. Cangrelor 9
10 Cangrelor Intravenous P2Y12 receptor antagonist Approved as adjunctive therapy for PCI to reduce the risk of periprocedural MI, repeat revascularization and stent thrombosis in patients who have not been treated with a P2Y12 inhibitor previously and are not being given a GP IIb/IIIa inhibitor. 30mcg/kg IV bolus followed by 4mcg/kg/min infusion for at least 2 hours or the duration of PCI (whichever is longer) Oral P2Y12 inhibitor should be administered as loading dose immediately after discontinuation of cangrelor infusion Short half-life Offset of platelet inhibition ~ 1hour Kengreal (Cangrelor). Package insert. The Medicine s Company Pharmacokinetics/Pharmacodynamics Kengreal (Cangrelor). Package insert. The Medicine s Company Clinical Studies Patient GPIIb/IIIa Inhibitor Cangrelor Dosing Population Use SIHD (15%), 30mcg/kg bolus UA/NSTEMI followed by Procedural permitted CHAMPION (74%), and 4mcg/kg/min; per treating physician PCI STEMI (11%) Procedure (26.5%) requiring PCI duration ( 2h) 30mcg/kg bolus SIHD (5%), followed by CHAMPION Used sparingly UA/NSTEMI 4mcg/kg/min PLATFORM (9.2%) (95%) during procedure (2-4 hours) 30mcg/kg bolus SIHD (58%), followed by CHAMPION - UA/NSTEMI Permitted as rescue 4mcg/kg/min ; PHOENIX (26%), STEMI therapy during PCI Procedure (16%) duration ( 2h) Oral P2Y12 Inhibitor Clopidogrel 600mg before PCI Clopidogrel 600mg after PCI or end of cangrelor Clopidogrel 300 or 600mg before or after PCI Primary Ischemic Outcome OR 1.05 ( ; p=0.59) OR 0.86 ( ; p=0.15) OR 0.78 ( ; p=0.005) N Engl J Med. 2009;361: N Engl J Med. 2009;361: N Engl J Med. 2013;368: TIMI Major or Minor Bleeding Major OR 1.36 ( , p=0.39) Minor OR 1.39 ( , p=0.21) Major OR 0.44 ( , p=0.17) Minor OR 1.37 ( , p=0.34) Major OR 1.0 ( , p>0.999) Minor OR 3.0 ( , p=0.08) 10
11 Cangrelor in Bridging Antiplatelet Therapy ACS patients s/p PCI on DAPT needing non-emergent CABG surgery Patients had received either loading or been on maintenance dose thienopyridine Randomized to either cangrelor or placebo Dosing of cangrelor titrated according to VerifyNow PRU results Goal antiplatelet effect <240PRU Dose range 0.5-2mcg/kg/min 0.75mcg/kg/min considered optimal Comparison No differences in bleeding outcomes JAMA. 2012;307: Cangrelor Not currently included in ACS guidelines issued by ACC/AHA European Society of Cardiology non-stemi Guidelines Cangrelor may be considered in P2Y12 inhibitor-naïve patients undergoing PCI (Class IIb, LOE A) May be useful in bridging P2Y12 inhibitor therapy prior to urgent/emergent surgery in patients who have recently undergone implantation of coronary stents (off-label) Eur Heart J. 2016;37: Who should get this? Patients undergoing PCI not pre-treated with oral p2y12inhibitor and not receiving GP IIb/IIIa inhibitor Patients unable to take oral medications undergoing PCI Patients with complicated interventions who may require subsequent coronary artery bypass graft surgery (off-label) Patients requiring surgical procedures for whom prolonged discontinuation of DAPT may be dangerous (off-label) Cardiac or urgent non-cardiac surgery 11
12 Vorapaxar Vorapaxar PAR-1 receptor antagonist inhibits thrombin-induced platelet aggregation PAR-1 and PAR-4 receptor mediate thrombin activation of platelet PAR-1 activated by lower concentration of thrombin, mediates more rapid platelet-activation response Clinical Studies Patient Population Vorapaxar dosing Background antiplatelet therapy Primary Ischemic Outcome TIMI Major or Minor Bleeding TRACER ACS (without STelevation) 40mg LD then 2.5mg daily Aspirin (>99%) Clopidogrel (91.8%) GP IIb/IIIa (20.9%) HR 0.92 (CI ; p=0.07) HR 1.53 (CI ; p<0.001) TRA 2P-TIMI 50 History of atherosclerosis; MI or ischemic stroke within 2 weeks to 12months or PAD 2.5mg daily Aspirin (80-98%) Thienopyridine (20-78%) HR 0.87 (CI ) HR 1.46 (CI ) N Engl J Med. 2011;366:20-33 N Engl J Med. 2012;366:
13 Vorapaxar Not included in ACC/AHA ACS guidelines ESC Guidelines indicate Benefit of vorapaxar is modest and must be carefully weighed against the increase bleeding events including intracranial hemorrhage Contraindicated in patients with cerebrovascular disease Eur Heart J. 2015; ACS guideline web addenda Patient Case JS attends his follow-up appointment with his cardiologist at 1 year following his NSTEMI and PCI. Patient has no complaints and appears to be doing well. Echocardiogram reveals his LVEF ~25-30% DAPT score calculated to be 3pts MI at presentation 1pt s/p PCI with stent placement 1pt Cigarette smoking 1pt HF or LVEF <30% 2pt Age now 75 YO -2pt Patient Case What would be the optimal treatment option with JS antiplatelet regimen? A. Continue aspirin only, discontinue ticagrelor B. Continue aspirin, switch ticagrelor to prasugrel 10mg daily C. Continue aspirin, switch ticagrelor 90mg BID to 60mg BID D. Discontinue all antiplatelet agents, patient has reached 1 year 13
14 Conclusions Aspirin dosing should be 325mg once initially followed by 81mg daily maintenance dose Choice of DAPT based on patient factors Ticagrelor or prasugrel may be moderately superior in ACS patients No prasugrel in patients with stroke/tia Duration should remain 12mo following ACS DAPT score may define Cangrelor represents a new IV P2Y12 receptor antagonist Lower risk of stent thrombosis + possibly higher risk of bleeding Routine place in therapy remains questionable Vorapaxar role in current therapy unclear Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY 14
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationTailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI
Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI Adel El-Etriby; MD Professor of Cardiology Ain Shams University President of the Egyptian Working Group of Interventional Cardiology
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationUpdate on Antiplatelet Therapy
Update on Antiplatelet Therapy Christine Ibarra Pharm.D. PGY-1 Baptist Hospital of Miami Objectives Explain the role of antiplatelettherapy in prevention of cardiovascular events Appreciate differences
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationTim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Σημαντικές Εξελίξεις στη Θρόμβωση 2014 2015 TRA 2P TIMI 50 και TRACER Substudies ΚΑΛΑΝΤΖΗ ΚΑΛΛΙΡΡΟΗ Καρδιολόγος ιδάκτωρ Ιατρικής Σχολής Πανεπιστημίου
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationΑντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationCase Challenges in ACS The Very Elderly in the Cath Lab
Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive
More informationAcute Coronary Syndromes Compendium
Acute Coronary Syndromes Compendium Circulation Research Compendium on Acute Coronary Syndromes Acute Coronary Syndromes: Pathology, Diagnosis, Genetics, Prevention, and Treatment Mechanisms of Plaque
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationAntiplatelet therapy is the mainstay of pharmacological
Contemporary Reviews in Interventional Cardiology Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era Review of the Evidence and Practice
More informationSTEMI 2014 YAHYA KIWAN. Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital
STEMI 2014 YAHYA KIWAN Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital Aspiration Thrombectomy Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI. I
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Case Presentation 46 year old
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationDAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders
DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders Annual Ohio ACC Conference October 14, 2017 Ernest L. Mazzaferri Jr, MD, FACC, FSCAI Disclosures No financial disclosures related to
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationSTEMI Presentation and Case Discussion. Case #1
STEMI Presentation and Case Discussion Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando, Florida September 17 th,
More informationCOPYRIGHT. Harvard Medical School
Agenda New Rapid Rule Out Strategy General Guidelines and Therapies Assessing Patient Risk Timing of Catheterization Navigating Anticoagulant/Antiplatelet Choices Newer Choices and new data The Future
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Outline Case Presentation STEMI
More informationOptimal Duration of Dual Anti- Platelet Therapy. December 19, 2015
Optimal Duration of Dual Anti- Platelet Therapy December 19, 2015 John S. MacGregor, M.D., Ph.D. Professor of Medicine University of California San Francisco Source: The New Yorker 1 Optimal Duration of
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationOral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,
More informationUnderstanding and Treating Acute Coronary Syndrome
Page 1 Understanding and Treating Acute Coronary Syndrome Jean M. Nappi, Pharm.D., FCCP, BCPS Professor of Clinical Pharmacy & Outcome Sciences South Carolina College of Pharmacy-MUSC Campus Professor
More informationDo We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationP 2 Y 12 Receptor Inhibitors
P 2 Y 12 Receptor Inhibitors Clopidogrel, Prasugrel and Ticagrelor Which Drug and for Whom? Cheol Whan Lee, MD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical
More informationDisclosures. Updates in Acute Coronary Syndromes 10/21/17. No Conflicts of Interest. Updates in Acute Coronary Syndromes. Krishan Soni, MD, MBA, FACC
Disclosures Updates in Acute Coronary Syndromes No Conflicts of Interest Krishan Soni, MD, MBA, FACC Assistant Professor of Medicine Division of Cardiology Krishan.soni@ucsf.edu Updates in Acute Coronary
More information10 Steps to Managing Non-ST Elevation ACS
Pathophysiology of Acute Coronary Syndromes and Potential Pharmacologic Interventions Acute Coronary Syndrome 4. Downstream from thrombus myocardial ischemia/necrosis (Beta-blockers, Nitrates etc) 3. Activation
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More informationSpeaker s name: Thomas Cuisset, MD, PhD
Speaker s name: Thomas Cuisset, MD, PhD X I have the following potential conflicts of interest to report: x Consulting: Daiichi Sankyo, Eli Lilly Employment in industry Stockholder of a healthcare company
More informationΔοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Ομάδες Εργασίας Φεβρουάριος 2016 Ξανθοπούλου Ιωάννα Καρδιολόγος Επιμ Β ΠΓΝΠατρών Nothing to disclose Platelet function testing (PFT) is helpful in identifying
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationAntithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France
Antithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France Disclosures Research grants: Astra-Zeneca, Merck, Novartis, Pfizer, sanofi-aventis, Servier, The MedCo Fees
More informationAntiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants
Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants S. Hinan Ahmed, MD Anti-platelet Therapy: Simple Answer Bare metal stent
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More informationDisclosures. Research consulting with: Sanofi-Regeneron Pfizer The Medicines Company Astra Zeneca
Antiplatelet Therapy in Coronary Artery Disease -2015 What are the roles for newer therapies? How do you decide what to cover? R. Scott Wright, MD, FACC, FESC, FAHA Professor of Medicine, Mayo Clinic College
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationNew antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy
Cairo, Egypt 2010 New antiplatelets in NSTEMI Steen D. Kristensen, FESC Department of Cardiology Aarhus University Hospital Skejby Denmark Overview: dual anti-platelet oral therapy Aspirin Clopidogrel
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationUpdate on STEMI Guidelines. Manesh R. Patel, MD Assistant Professor of Medicine Duke University Medical Center
Update on STEMI Guidelines Manesh R. Patel, MD Assistant Professor of Medicine Duke University Medical Center All Rights Reserved, Duke Medicine 2008 Disclosures Research Grants: NHLB, AHRQ, AstraZeneca,
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More informationThe Great debate: thrombocardiology post-compass
The Great debate: thrombocardiology post-compass Anticoagulation should replace antiplatelets in CAD prevention - CON Jean-Philippe COLLET Jean-philippe.collet@psl.aphp.fr Sorbonne Université_Action Study
More informationA Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 1
More informationACUTE CORONARY SYNDROME
A supplement to MONTHLY PRESCRIBING REFERENCE April 2014 Issue #18 Intervention & Prevention: Keeping Current with ACUTE CORONARY SYNDROME JOURNAL CLUB Pretreatment with prasugrel in non-st-segment elevation
More informationINNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies.
INNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies. José G. Díez, MD, FACC, FSCAI Associate Professor of Medicine, Baylor College of Medicine Hall Garcia
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationClinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition
Clinical Case Management of ACS Based on ACC/AHA & ESC Guidelines Dr Badri Paudel Mr M 75M Poorly controlled diabetic Smoker Presented on Sat 7pm Intense burning in the retrosternal area Clinical Case
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More information2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation Thierry Gillebert European Society of Cardiology, Slides kindly provided
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationISCHEMIC HEART DISEASE
ESC CONGRESS HIGHLIGHTS ISCHEMIC HEART DISEASE Francesco Cosentino (Stockholm, S) Declaration of Interest Advisory Board/Speaker: AstraZeneca, Roche, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck,
More informationAntiplatelet in diabetics: strong but incomplete umbrella
Antiplatelet in diabetics: strong but incomplete umbrella Seung-Whan Lee, MD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Global Projections for the Number
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationMINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More information